Safety of the Subretinal Delivery of RGX-314 AAV8-anti-VEGF Fab Gene Therapy in NHP: Retinal Structure Over One Year
Michael J. Ammar(Thomas Jefferson University), Tomás S. Alemán(Children's Hospital of Philadelphia), Leah Makaron(University of Pennsylvania), James M. Wilson(St Bartholomew's Hospital), Jean Bennett(Penn Presbyterian Medical Center), Erin Bote(University of Pennsylvania), Erik Wielechowski(University of Pennsylvania), Katherine E. Uyhazi(Penn Presbyterian Medical Center), Elaine Zhou(University of Pennsylvania), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Albert M. Maguire(Children's Hospital of Philadelphia), Stephen Yoo(Cedars-Sinai Medical Center), Jessica Ijams Wolfing Morgan(Penn Presbyterian Medical Center), Anna Tretiakova(Pfizer (United States)), Arkady Lyubarsky(Penn Presbyterian Medical Center)
Investigative Ophthalmology & Visual Science
July 13, 2018
Cited by 2
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703